Last10K.com

Aerpio Pharmaceuticals, Inc. (ARPO) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

Aerpio Pharmaceuticals, Inc.

CIK: 1607678 Ticker: ARPO

Exhibit 99.1

 

LOGO

Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021

Conference Call and Webcast Today, March 16, 2020 at 8:30 a.m. EST

CINCINNATI, Ohio, March 16, 2020 – Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the fourth quarter and full year ended December 31, 2019.

“We ended the year with a strong cash position, $38.5 million, and with promising results in our Phase 1b glaucoma clinical trial,” said Joseph Gardner, Ph.D., President and Founder of Aerpio. “A mean reduction in intraocular pressure of 1.58 mmHg on top of standard of care prostaglandins, was observed in cohort five which included patients with ocular hypertension (OH) and primary open angle glaucoma patients (OAG). The mean intraocular pressure (IOP) reduction was statistically significant after only 7 days of dosing and the tolerability was favorable with minimal hyperemia. These results set us up to run a Phase 2 trial starting in the third quarter of this year. We have reviewed the study results with glaucoma experts who support moving forward with further development. Once initiated, we expect topline results from this trial to read out in the first quarter of 2021.”

2019 Company Highlights

 

   

Completed a Phase 1b clinical trial designed to assess the safety of the Company’s lead candidate, AKB-9778 in the form of topical ocular drops, for patients with OAG and OH.

 

   

Presented promising IOP lowering data from the Company’s Phase 1b clinical trial of topical ocular formulation of AKB-9778 in patients with OAG and OH in February 2020 at the Glaucoma 360 conference in San Francisco. The IOP lowering activity observed in the Phase 1b trial when AKB-9778 was combined with a prostaglandin appeared comparable to or better than published Phase 3 data for marketed adjuvant therapies.

 

   

Restructured the Company to preserve cash and provide flexibility to explore potential strategic alternatives.


The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Monday, March 16, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aerpio Pharmaceuticals, Inc..

Continue

Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (Detail)
Common Stock
Common Stock - Additional Information (Detail)
Employee Bonus Plan
Employee Bonus Plan - Additional Information (Detail)
Employee Retirement Plan
Employee Retirement Plan - Additional Information (Detail)
Employee Stock Purchase Plan
Employee Stock Purchase Plan - Additional Information (Detail)
Furniture And Equipment
Furniture And Equipment (Tables)
Furniture And Equipment - Summary Of Components Of Furniture And Equipment (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Reconciliation Of Statutory Federal Income Tax (Detail)
Income Taxes - Schedule Of Significant Components Of Deferred Tax Assets And Liabilities (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Schedule Of Future Payments Related To Operating Leases Activities (Detail)
Leases - Summary Of Lease Cost And Information Related To The Right-Of-Use Assets And Operating Lease Liabilities (Detail)
License Agreement
License Agreement - Additional Information (Detail)
Nature Of Organization And Operations
Nature Of Organization And Operations - Additional Information (Detail)
Net And Comprehensive Loss Per Share Attributable To Common Stockholders
Net And Comprehensive Loss Per Share Attributable To Common Stockholders (Tables)
Net And Comprehensive Loss Per Share Attributable To Common Stockholders - Schedule Of Computation Of Basic And Diluted Net And Comprehensive Loss Per Share (Detail)
Net And Comprehensive Loss Per Share Attributable To Common Stockholders - Schedule Of Weighted Average Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (Detail)
Preferred Stock
Preferred Stock - Additional Information (Detail)
Quarterly Results (Unaudited)
Quarterly Results (Unaudited) (Tables)
Quarterly Results (Unaudited) - Additional Information (Detail)
Quarterly Results (Unaudited) - Summary Of Unaudited Quarterly Results (Detail)
Restructuring
Restructuring - Additional Information (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Stock Options Valuation Assumptions (Detail)
Stock-Based Compensation - Summary Of Recognized Compensation Cost Related To Employee And Non-Employee Stock-Based Compensation Activity (Detail)
Stock-Based Compensation - Summary Of Restricted Stock Activity (Detail)
Stock-Based Compensation - Summary Of Stock Option Activity (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Assets Measured On Recurring Basis (Detail)
Ticker: ARPO
CIK: 1422142
Form Type: 10-K Annual Report
Accession Number: 0001564590-20-011174
Submitted to the SEC: Mon Mar 16 2020 4:31:43 PM EST
Accepted by the SEC: Mon Mar 16 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/arpo/0001564590-20-011174.htm